

Jason S Mclellan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9092048/jason-s-mclellan-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

139 papers	17,201 citations	52 h-index	131 g-index
157 ext. papers	23,057 ext. citations	16.7 avg, IF	7.44 L-index

#	Paper	IF	Citations
139	Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies. <i>Science</i> , 2022 , 375, 104-109	33.3	2
138	Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies.. <i>Science Advances</i> , 2022 , 8, eabm2546	14.3	0
137	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.. <i>EClinicalMedicine</i> , 2022 , 45, 101323	11.3	4
136	The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes.. <i>Nature Structural and Molecular Biology</i> , 2022 ,	17.6	6
135	Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking.. <i>Nature Biotechnology</i> , 2022 ,	44.5	6
134	Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins.. <i>Nature Communications</i> , 2022 , 13, 1299	17.4	1
133	Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry.. <i>Analytical Chemistry</i> , 2022 ,	7.8	2
132	Protein engineering responses to the COVID-19 pandemic.. <i>Current Opinion in Structural Biology</i> , 2022 , 74, 102385	8.1	0
131	Cryo-EM structure of the EBV ribonucleotide reductase BORF2 and mechanism of APOBEC3B inhibition.. <i>Science Advances</i> , 2022 , 8, eabm2827	14.3	1
130	Principles and practical applications of structure-based vaccine design. <i>Current Opinion in Immunology</i> , 2022 , 77, 102209	7.8	1
129	A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. <i>MBio</i> , 2021 , 12, e0247321	7.8	11
128	Expression and characterization of SARS-CoV-2 spike proteins. <i>Nature Protocols</i> , 2021 , 16, 5339-5356	18.8	4
127	Stabilized coronavirus spike stem elicits a broadly protective antibody. <i>Cell Reports</i> , 2021 , 37, 109929	10.6	18
126	Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic. <i>Journal of Molecular Biology</i> , 2021 , 434, 167332	6.5	1
125	Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. <i>Clinical Infectious Diseases</i> , 2021 , 73, e4400-e4408	11.6	30
124	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines 2021 ,		12
123	Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus. <i>Journal of Immunology</i> , 2021 , 206, 2122-2134	5.3	1

122	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. <i>Nature</i> , 2021 , 594, 253-258	50.4	92
121	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	169
120	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. <i>Immunity</i> , 2021 , 54, 769-780.e6	32.3	9
119	Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality 2021 ,		4
118	A vulnerable, membrane-proximal site in human respiratory syncytial virus F revealed by a prefusion-specific single-domain antibody. <i>Journal of Virology</i> , 2021 ,	6.6	2
117	Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. <i>Science</i> , 2021 , 372, 1108-1112	33.3	100
116	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. <i>Cell Reports Medicine</i> , 2021 , 2, 100313	18	24
115	Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. <i>Cell</i> , 2021 , 184, 3486-3501.e21	56.2	8
114	Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking 2021 ,		2
113	Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. <i>Nature Communications</i> , 2021 , 12, 469	17.4	74
112	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. <i>Science</i> , 2021 , 371, 823-829	33.3	157
111	A glycan gate controls opening of the SARS-CoV-2 spike protein 2021 ,		22
110	Prolonged evolution of the human B cell response to SARS-CoV-2 infection. <i>Science Immunology</i> , 2021 , 6,	28	70
109	Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates 2021 ,		7
108	Local computational methods to improve the interpretability and analysis of cryo-EM maps. <i>Nature Communications</i> , 2021 , 12, 1240	17.4	13
107	A glycan gate controls opening of the SARS-CoV-2 spike protein. <i>Nature Chemistry</i> , 2021 , 13, 963-968	17.6	63
106	SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	106
105	Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial 2021 ,		5

104	Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. <i>Cell Reports</i> , 2021 , 37, 109784	10.6	7
103	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. <i>Science Immunology</i> , 2021 , 6, eabj2901	28	22
102	Structural basis for antibody binding to adenylate cyclase toxin reveals RTX linkers as neutralization-sensitive epitopes. <i>PLoS Pathogens</i> , 2021 , 17, e1009920	7.6	2
101	Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. <i>Nature Communications</i> , 2021 , 12, 5652	17.4	11
100	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021 , 184, 5432-5447.e16	56.2	34
99	Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies. <i>Science</i> , 2021 , eabl6502	33.3	0
98	Site-specific glycan analysis of the SARS-CoV-2 spike. <i>Science</i> , 2020 , 369, 330-333	33.3	768
97	Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. <i>Cell</i> , 2020 , 181, 1004-1015.e15	56.2	319
96	Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38. <i>Journal of Virology</i> , 2020 , 94,	6.6	11
95	Immunogenicity of a DNA vaccine candidate for COVID-19. <i>Nature Communications</i> , 2020 , 11, 2601	17.4	361
94	Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. <i>PLoS ONE</i> , 2020 , 15, e0232757	3.7	9
93	Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. <i>Nature Communications</i> , 2020 , 11, 2688	17.4	174
92	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. <i>Frontiers in Immunology</i> , 2020 , 11, 842	8.4	11
91	Broad neutralization of SARS-related viruses by human monoclonal antibodies. <i>Science</i> , 2020 , 369, 731-736	33.3	376
90	Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization. <i>Journal of Virology</i> , 2020 , 94,	6.6	16
89	Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers. <i>Cell Reports</i> , 2020 , 30, 4540-4550.e3	10.6	27
88	Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. <i>Science</i> , 2020 , 367, 1260-1263	33.3	5176
87	Continuous flexibility analysis of SARS-CoV-2 spike prefusion structures. <i>IUCrJ</i> , 2020 , 7,	4.7	25

86	Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation 2020 ,		143
85	Site-specific analysis of the SARS-CoV-2 glycan shield 2020 ,		74
84	Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein 2020 ,		18
83	Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes 2020 ,		27
82	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness 2020 ,		62
81	Beyond Shielding: The Roles of Glycans in SARS-CoV-2 Spike Protein 2020 ,		27
80	Continuous flexibility analysis of SARS-CoV-2 Spike prefusion structures 2020 ,		9
79	Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area 2020 ,		11
78	LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection 2020 ,		64
77	An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19 2020 ,		11
76	Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions 2020 ,		7
75	Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma 2020 ,		29
74	SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma 2020 ,		153
73	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020 , 586, 567-571	50.4	594
72	Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens. <i>Processes</i> , 2020 , 8, 1539	2.9	10
71	Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. <i>Science</i> , 2020 , 369, 1501-1505	33.3	450
70	Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step. <i>PLoS Pathogens</i> , 2020 , 16, e1008736	7.6	5
69	Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. <i>MBio</i> , 2020 , 11,	7.8	69

68	Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. <i>ACS Central Science</i> , 2020 , 6, 1722-1734	16.8	340
67	Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step 2020 , 16, e1008736		
66	Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step 2020 , 16, e1008736		
65	Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step 2020 , 16, e1008736		
64	Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step 2020 , 16, e1008736		
63	Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD. <i>Cell Reports</i> , 2019 , 28, 3395-3405.e6	10.6	53
62	Structure-Based Vaccine Antigen Design. <i>Annual Review of Medicine</i> , 2019 , 70, 91-104	17.4	91
61	Respiratory syncytial virus entry and how to block it. <i>Nature Reviews Microbiology</i> , 2019 , 17, 233-245	22.2	72
60	Transient opening of trimeric prefusion RSV F proteins. <i>Nature Communications</i> , 2019 , 10, 2105	17.4	29
59	A proof of concept for structure-based vaccine design targeting RSV in humans. <i>Science</i> , 2019 , 365, 505-509	39.9	118
58	Alternative conformations of a major antigenic site on RSV F. <i>PLoS Pathogens</i> , 2019 , 15, e1007944	7.6	15
57	Iterative screen optimization maximizes the efficiency of macromolecular crystallization. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2019 , 75, 123-131	1.1	8
56	Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B. <i>Pathogens and Immunity</i> , 2019 , 4, 294-323	4.9	9
55	The 3.1-Angstrom Cryo-electron Microscopy Structure of the Porcine Epidemic Diarrhea Virus Spike Protein in the Prefusion Conformation. <i>Journal of Virology</i> , 2019 , 93,	6.6	40
54	A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry. <i>Journal of Virological Methods</i> , 2019 , 265, 77-83	2.6	8
53	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. <i>Journal of Virology</i> , 2018 , 92,	6.6	119
52	Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation. <i>Immunity</i> , 2018 , 48, 339-349.e5	32.3	82
51	Chimeric fusion proteins as immunogens to induce cross-neutralizing antibody responses. <i>EMBO Molecular Medicine</i> , 2018 , 10, 175-187	12	3

50	Global site-specific analysis of glycoprotein N-glycan processing. <i>Nature Protocols</i> , 2018 , 13, 1196-1212	18.8	40
49	Clinical Potential of Prefusion RSV F-specific Antibodies. <i>Trends in Microbiology</i> , 2018 , 26, 209-219	12.4	28
48	Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F Subunit Are Critical for Its Fusion Activity. <i>Journal of Virology</i> , 2018 , 92,	6.6	9
47	Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies. <i>PLoS Pathogens</i> , 2018 , 14, e1006935	7.6	35
46	The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. <i>Lancet Infectious Diseases</i> , 2018 , 18, e295-e311	25.5	218
45	Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. <i>Scientific Reports</i> , 2018 , 8, 15701	4.9	259
44	Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex. <i>Journal of Virology</i> , 2017 , 91,	6.6	46
43	Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. <i>Nature Communications</i> , 2017 , 8, 14158	17.4	41
42	A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	113
41	Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater Protection than the Murine Precursor of Palivizumab. <i>Journal of Virology</i> , 2017 , 91,	6.6	18
40	Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate. <i>Journal of Virology</i> , 2017 , 91,	6.6	23
39	Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus. <i>MBio</i> , 2017 , 8,	7.8	17
38	Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. <i>Nature Communications</i> , 2017 , 8, 167	17.4	41
37	Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E7348-E7357	11.5	615
36	Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. <i>Nature Communications</i> , 2017 , 8, 1877	17.4	37
35	Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. <i>Nature Communications</i> , 2017 , 8, 1528	17.4	50
34	Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. <i>Vaccine</i> , 2017 , 35, 461-468	4.1	35
33	RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017 , 13, 411-420	6	23

32	Molecular mechanism of respiratory syncytial virus fusion inhibitors. <i>Nature Chemical Biology</i> , 2016 , 12, 87-93	11.7	84
31	Structural and molecular basis for Ebola virus neutralization by protective human antibodies. <i>Science</i> , 2016 , 351, 1343-6	33.3	134
30	Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. <i>PLoS Pathogens</i> , 2016 , 12, e1005859	7.6	24
29	Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. <i>Science Immunology</i> , 2016 , 1,	28	120
28	Pre-fusion structure of a human coronavirus spike protein. <i>Nature</i> , 2016 , 531, 118-21	50.4	474
27	Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector. <i>Journal of Virology</i> , 2016 , 90, 10022-10038	6.6	24
26	Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate. <i>Journal of Virology</i> , 2015 , 89, 9499-510	6.6	43
25	Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. <i>Current Opinion in Virology</i> , 2015 , 11, 70-5	7.5	64
24	A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. <i>Nature Communications</i> , 2015 , 6, 8143	17.4	174
23	Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. <i>Science Translational Medicine</i> , 2015 , 7, 309ra162	17.5	202
22	A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. <i>PLoS ONE</i> , 2015 , 10, e0128779	3.7	32
21	Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. <i>PLoS Pathogens</i> , 2015 , 11, e1005035	7.6	87
20	Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. <i>Science</i> , 2013 , 340, 1113-7	33.3	483
19	Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. <i>Science</i> , 2013 , 342, 592-8	33.3	531
18	Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. <i>Immunity</i> , 2013 , 38, 176-86	32.3	319
17	Structure and function of respiratory syncytial virus surface glycoproteins. <i>Current Topics in Microbiology and Immunology</i> , 2013 , 372, 83-104	3.3	159
16	Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. <i>Journal of Molecular Biology</i> , 2011 , 409, 853-66	6.5	90
15	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011 , 480, 336-43	50.4	682

14	Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. <i>Journal of Virology</i> , 2011 , 85, 7788-96	6.6	268
13	Structural basis of respiratory syncytial virus neutralization by motavizumab. <i>Nature Structural and Molecular Biology</i> , 2010 , 17, 248-50	17.6	121
12	Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. <i>Journal of Virology</i> , 2010 , 84, 12236-44	6.6	83
11	Trimeric SARS-CoV-2 Spike proteins produced from CHO-cells in bioreactors are high quality antigens		1
10	Receptor binding and proteolysis do not induce large conformational changes in the SARS-CoV spike		1
9	Vulnerabilities in coronavirus glycan shields despite extensive glycosylation		13
8	Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies		10
7	Molecular Architecture of Early Dissemination and Evolution of the SARS-CoV-2 Virus in Metropolitan Houston, Texas		12
6	Local computational methods to improve the interpretability and analysis of cryo-EM maps		2
5	Structural basis for HCMV Pentamer recognition by antibodies and neuropilin 2		1
4	Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition		1
3	A combination of RBD and NTD neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants		2
2	The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes		3
1	Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses		14